LGALS3 and infection: The results showed that galectin-3 was not associated with long-term outcomes in the ≥90 mL/min per 1.73 m2 group in the LURIC study [46], but that it was significantly associated with all-cause mortality, cardiovascular mortality, death due to infection, and sudden cardiac death in patients with eGFR of 60–89 mL/min per 1.73 m2.